Cwm LLC Purchases 1,358 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Cwm LLC boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 415.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,685 shares of the company’s stock after acquiring an additional 1,358 shares during the quarter. Cwm LLC’s holdings in Syndax Pharmaceuticals were worth $36,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its stake in shares of Syndax Pharmaceuticals by 47.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 390,538 shares of the company’s stock valued at $5,671,000 after purchasing an additional 125,893 shares during the last quarter. Hudson Bay Capital Management LP raised its stake in Syndax Pharmaceuticals by 160.2% during the third quarter. Hudson Bay Capital Management LP now owns 1,236,186 shares of the company’s stock worth $17,949,000 after acquiring an additional 761,186 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Syndax Pharmaceuticals by 2.7% in the 3rd quarter. Wellington Management Group LLP now owns 7,642,446 shares of the company’s stock valued at $110,968,000 after purchasing an additional 198,262 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Syndax Pharmaceuticals by 57.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 206,394 shares of the company’s stock valued at $2,997,000 after purchasing an additional 75,636 shares during the last quarter. Finally, Jump Financial LLC grew its holdings in shares of Syndax Pharmaceuticals by 326.6% during the 3rd quarter. Jump Financial LLC now owns 154,786 shares of the company’s stock valued at $2,247,000 after purchasing an additional 118,500 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. StockNews.com raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. Citigroup lowered their target price on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Thursday. Stifel Nicolaus raised their price objective on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $34.42.

Syndax Pharmaceuticals Stock Down 1.8 %

SNDX stock opened at $21.97 on Friday. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -7.42 and a beta of 1.01. The company’s fifty day simple moving average is $22.44 and its 200 day simple moving average is $20.17. Syndax Pharmaceuticals, Inc. has a 12-month low of $11.22 and a 12-month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.11. During the same period last year, the company earned ($0.59) earnings per share. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.74 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).